4D Molecular Therapeutics (FDMT) Operating Leases (2021 - 2026)

4D Molecular Therapeutics (FDMT) has 6 years of Operating Leases data on file, last reported at $15.0 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $15.0 million, down 17.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.0 million (down 17.19% YoY), and the FY2025 annual result was $15.8 million, down 16.6% from the prior year.
• Operating Leases retreated to $15.0 million in Q1 2026 per FDMT's latest filing, from $15.8 million in the prior quarter.
• Over five years, Operating Leases peaked at $19.7 million in Q3 2024 and troughed at $10.5 million in Q2 2024.
• A 5-year average of $14.6 million and a median of $14.4 million in 2022 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2025 and 2026: Operating Leases surged 65.93% in 2025, then slipped 17.19% in 2026.
• A 5-year view of Operating Leases shows it stood at $13.5 million in 2022, then dropped by 14.46% to $11.5 million in 2023, then jumped by 64.63% to $19.0 million in 2024, then declined by 16.6% to $15.8 million in 2025, then retreated by 4.88% to $15.0 million in 2026.
• Business Quant data shows FDMT's Operating Leases at $15.0 million in Q1 2026, $15.8 million in Q4 2025, and $16.6 million in Q3 2025.